lava-flow
1 April 2013AsiaRahul Vartak

Slow but positive change? The evolution of section 3d

The Indian pharmaceutical scene has been plagued by Section 3d of the Indian Patents Act for almost a decade. Section 3d has been wielded skilfully by various companies for challenging pharmaceutical patents. Various tactics have been used by innovators for overcoming the challenges posed by Section 3d, including a challenge to TRIPS compliance and constitutional validity. However, Section 3d has been able to withstand all challenges.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
6 January 2026   Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.
Asia
9 December 2025   The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.
Asia
4 December 2025   The Delhi High Court has denied an injunction against an Indian generic manufacturer, finding credible challenges to the validity of Novo's semaglutide patent—flagging concerns over obviousness, double patenting, and evergreening.